Loading company…
MeiraGTx, based in New York, develops genetic medicines using its riboswitch gene regulation platform.
Founded in 2015 and headquartered in New York, US, MeiraGTx Holdings plc is a biotechnology company focused on genetic therapies. Its riboswitch platform controls gene expression for treating inherited diseases. The company reported revenue of USD 14.02 mn and EBITDA of USD -122.07 mn in 2023. In June 2018 it raised USD 30.00 mn from investors including Sanofi Ventures, and Zandy Forbes is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in